Pharmaceutical products will be spared from sweeping tariffs on major U.S. trade partners for now, a small victory for drug companies who have been lobbying for an exemption from levies.

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...